{'52WeekChange': 0.8011153,
 'SandP52WeekChange': 0.0644362,
 'address1': '490 Arsenal Way',
 'address2': 'Suite 210',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.96,
 'askSize': 1400,
 'averageDailyVolume10Day': 398737,
 'averageVolume': 991674,
 'averageVolume10days': 398737,
 'beta': 3.688841,
 'beta3Year': None,
 'bid': 0.9501,
 'bidSize': 3100,
 'bookValue': 0.351,
 'category': None,
 'circulatingSupply': None,
 'city': 'Watertown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.9779,
 'dayLow': 0.91,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.696,
 'enterpriseToRevenue': None,
 'enterpriseValue': 20418786,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617-995-2410',
 'fiftyDayAverage': 1.1123714,
 'fiftyTwoWeekHigh': 1.99,
 'fiftyTwoWeekLow': 0.25,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 15387614,
 'forwardEps': -0.56,
 'forwardPE': -1.730357,
 'fromCurrency': None,
 'fullTimeEmployees': 13,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.26524,
 'heldPercentInstitutions': 0.16285999,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aileronrx.com',
 'longBusinessSummary': 'Aileron Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing and '
                        'commercializing a novel class of stabilized '
                        'cell-permeating alpha-helical peptides in the '
                        'oncology and other therapeutic areas in the United '
                        "States. The company's lead product candidate is "
                        'ALRN-6924, a cell-permeating peptide, which is in '
                        'Phase 2a clinical trial for the treatment of advanced '
                        'solid tumors; Phase 2a clinical trial to treat '
                        'peripheral T-cell lymphoma; Phase I clinical trial '
                        'for the treatment of acute myeloid leukemia (AML) and '
                        'advanced myelodysplastic syndrome (MDS); and Phase 1b '
                        'trial to test the combination of ALRN-6924 and '
                        'cytarabine, or Ara-C, in patients with MDS. It also '
                        'develops next generation wild type p53 reactivator. '
                        'Aileron Therapeutics, Inc. has a collaboration '
                        "agreement with Dana-Farber/Boston Children's Cancer "
                        'and Blood Disorders Center for an open-label, '
                        'multi-center, pediatric phase 1 clinical trial of '
                        'ALRN-6924; and Pfizer to evaluate the combination of '
                        'ALRN-6924 and IBRANCE in MDM2-amplified cancers. The '
                        'company was formerly known as Renegade Therapeutics, '
                        'Inc. and changed its name to Aileron Therapeutics, '
                        'Inc. in February 2007. Aileron Therapeutics, Inc. was '
                        'founded in 2001 and is headquartered in Watertown, '
                        'Massachusetts.',
 'longName': 'Aileron Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 38031796,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_21766697',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -28904000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.94,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.66,
 'phone': '617-995-0900',
 'previousClose': 0.952,
 'priceHint': 4,
 'priceToBook': 2.7606835,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.9779,
 'regularMarketDayLow': 0.91,
 'regularMarketOpen': 0.94,
 'regularMarketPreviousClose': 0.952,
 'regularMarketPrice': 0.94,
 'regularMarketVolume': 333852,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39248500,
 'sharesPercentSharesOut': 0.0222,
 'sharesShort': 870944,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 606700,
 'shortName': 'Aileron Therapeutics, Inc.',
 'shortPercentOfFloat': 0.026600001,
 'shortRatio': 0.59,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ALRN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.04,
 'twoHundredDayAverage': 0.7521511,
 'volume': 333852,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aileronrx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02472'}